Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinblastine monotherapy for standard-risk ALK-positive pediatric ALCL
2017-002935-40Phase 3Active
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vinblastine in anaplastic large cell lymphoma (ALCL), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: 3-year event-free survival. Started Jan 2020; status: active.
02
Drugs
vinblastine
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2017-002935-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002935-40.